TNFRSF17 and hematologic disorder: Chimeric antigen receptor (CAR) T cell therapy, a form of ATC therapies that involves genetically modifying T cells with CARs to target tumor-associated antigens (TAAs), has demonstrated significant attention due to its promising clinical outcomes in hematological malignancies, mainly targeting CD19 and B-cell maturation antigen (BCMA), leading to Food and Drug Administration (FDA) approval for B-cell malignancies [10].